ReviewIndian journal of pediatrics2020
Immune Thrombocytopenia in Children: Consensus and Controversies.
Review in Indian journal of pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis.Frontiers in immunology · 2025Pooled it
- Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia.British journal of haematology · 2026Observational
- Health-related quality of life in Chinese children with immune thrombocytopaenia: a multicentre study.BMJ paediatrics open · 2026Article
- The role of T Cell Immunoglobulin Mucin Domain-3 in children with immune thrombocytopenia.BMC pediatrics · 2026Article
- CpG can induce the proliferation and differentiation of B10 cells in the peripheral blood of children with immune thrombocytopenic purpura.Annals of hematology · 2025Article
- The expression pattern and role of circulating CXCR5Frontiers in pediatrics · 2025Article
- Pentavalent Vaccine-Induced Immune Thrombocytopenia: A Case Report From Nepal.Clinical case reports · 2025Article
- Effect of nursing risk management on treatment compliance and family psychological status in pediatric patients with idiopathic thrombocytopenic purpura.American journal of translational research · 2025Article
- Article
- Immune thrombocytopenic purpura secondary to varicella zoster virus.BMJ case reports · 2023Article
- Regulatory T-lymphocyte subsets in children with chronic immune thrombocytopenia after high-dose of dexamethasone.Pediatric research · 2022Article
- [Expression of miR-106b-5p in children with primary immune thrombocytopenia and its correlation with T cells].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- The Use of Clinical Scores in the Management of Immune Thrombocytopenic Purpura in Children.Frontiers in pediatrics · 2022Review
- Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.Blood advances · 2021Observational
- Use of bioinformatic analyses in identifying characteristic genes and mechanisms active in the progression of idiopathic thrombocytopenic purpura in individuals with different phenotypes.The Journal of international medical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newly diagnosed immune thrombocytopenia (ITP) is a relatively common disorder of childhood that does not require an exhaustive laboratory workup for diagnosis. A history and physical exam with a review of the peripheral smear are crucial for excluding secondary causes of thrombocytopenia. Several guidelines have been published to guide physicians in the management of ITP. However, the decision for treatment can be arduous. The management strategy should not be focussed on the platelet count but the severity of bleeding symptoms. Agents for treating acute ITP, including corticosteroids, immunoglobulin and anti-D immunoglobulin, do not seem to have a significant impact on the natural history of the disease. The majority of children with ITP do not need therapy and have a spontaneous resolution of the disease. Some children can develop chronic ITP that is not commonly life-threatening but can lead to impaired quality of life. Traditional therapies such as rituximab and splenectomy for chronic ITP are not without significant adverse effects. Thrombopoietin receptor agonists are newer agents for the treatment of chronic ITP and hold promise, however, their cost currently precludes use in most of the patients in low-middle-income countries. This review compares and contrasts the specific treatments available for the treatment of ITP to help the reader make a balanced choice. This review, based on a series of case examples, will help physicians in making decisions about choosing a practical management strategy for patients with newly diagnosed as well as chronic ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.